Ayala Pharmaceuticals

General Information


We are a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. Our current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors.

Employees: 29
Founded: 2017
Contact Information
Address Oppenheimer 4, Rehovot 7670104, Israel
Phone Number +972-8-373-1541
Web Address http://www.ayalapharma.com
View Prospectus: Ayala Pharmaceuticals
Financial Information
Market Cap $186.7mil
Revenues $2.3 mil (last 12 months)
Net Income $-17.8 mil (last 12 months)
IPO Profile
Symbol AYLA
Exchange NASDAQ
Shares (millions): 3.7
Price range $15.00 - $15.00
Est. $ Volume $55.0 mil
Manager / Joint Managers Citigroup/ Jefferies
CO-Managers Oppenheimer & Co./ Raymond James
Expected To Trade: 5/8/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change